Phase II trial of weekly docetaxel and carboplatin as first line chemotherapy in advanced or metastatic non small cell lung cancer (NSCLC)

7330 Background: Single-agent platinum therapy has been the backbone treatment in NSCLC. With the emergence of new cytotoxic agents such as Docetaxel, new combinations were evaluated. The concomita...